Evidence map›Paper›PMID 34361047›Full record

ArticleInternational journal of molecular sciences2021

Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?

Katarina Kalavska, Zuzana Sestakova, Andrea Mlcakova, Katarína Kozics, Paulina Gronesova, Lenka Hurbanova, Viera Miskovska, Katarina Rejlekova, Daniela Svetlovska, Zuzana Sycova-Mila and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Katarina KalavskaTranslational Research Unit, Faculty of Medicine, Comenius University, National Cancer Institute, 833 10 Bratislava, Slovakia.
Zuzana SestakovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovakia.
Andrea MlcakovaDepartment of Hematology, National Cancer Institute, 833 10 Bratislava, Slovakia.
Katarína KozicsDepartment of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovakia.
Paulina GronesovaDepartment of Immunology, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovakia.
Lenka HurbanovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovakia.
Viera Miskovska1st Department of Oncology, Faculty of Medicine, Comenius University, St. Elisabeth Cancer Institute, 812 50 Bratislava, Slovakia.
Katarina Rejlekova2nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, 833 10 Bratislava, Slovakia.
Daniela SvetlovskaTranslational Research Unit, Faculty of Medicine, Comenius University, National Cancer Institute, 833 10 Bratislava, Slovakia.
Zuzana Sycova-MilaDepartment of Oncology, National Cancer Institute, 833 10 Bratislava, Slovakia.
Jana ObertovaDepartment of Oncology, National Cancer Institute, 833 10 Bratislava, Slovakia.
Patrik PalackaDepartment of Oncology, National Cancer Institute, 833 10 Bratislava, Slovakia.
Jozef MardiakDepartment of Oncology, National Cancer Institute, 833 10 Bratislava, Slovakia.
Michal Chovanec2nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, 833 10 Bratislava, Slovakia.ORCID 0000-0002-5653-2909
Miroslav ChovanecDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy Sciences, 845 05 Bratislava, Slovakia.ORCID 0000-0001-9120-5084
Michal MegoTranslational Research Unit, Faculty of Medicine, Comenius University, National Cancer Institute, 833 10 Bratislava, Slovakia.ORCID 0000-0002-6511-6827
Cancer Research Institute of the Slovak Academy of Sciences · SKComenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance of germ cell tumors (GCTs) represents an intensively studied property of GCTs that is the result of a complicated multifactorial process. One of the driving factors in this process is the tumor microenvironment (TME). Intensive crosstalk between the DNA damage/DNA repair pathways and the TME has already been reported. This study aimed at evaluating the interplay between the immune TME and endogenous DNA damage levels in GCT patients. A cocultivation system consisting of peripheral blood mononuclear cells (PBMCs) from healthy donors and GCT cell lines was used in an in vitro study. The patient cohort included 74 chemotherapy-naïve GCT patients. Endogenous DNA damage levels were measured by comet assay. Immunophenotyping of leukocyte subpopulations was performed using flow cytometry. Statistical analysis included data assessing immunophenotypes, DNA damage levels and clinicopathological characteristics of enrolled patients. The DNA damage level in PBMCs cocultivated with cisplatin (CDDP)-resistant GCT cell lines was significantly higher than in PBMCs cocultivated with their sensitive counterparts. In GCT patients, endogenous DNA damage levels above the cutoff value were independently associated with increased percentages of natural killer cells, CD16-positive dendritic cells and regulatory T cells. The crosstalk between the endogenous DNA damage level and specific changes in the immune TME reflected in the blood of GCT patients was revealed. The obtained data contribute to a deeper understanding of ongoing interactions in the TME of GCTs.

Indexed as

DNA DamageAdultAntineoplastic AgentsBiomarkers, TumorCell Line, TumorCisplatinDrug Resistance, NeoplasmHumansLeukocytes, MononuclearMaleMiddle AgedTesticular NeoplasmsTumor MicroenvironmentAntineoplastic AgentsBiomarkers, TumorCisplatinDNA damage levelgerm cell tumorsimmune microenvironmenttumor microenvironment

Identifiers

PMID34361047
PMCPMC8347719
OpenAlexW3188707935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.